Juno: Centralised approach key to manufacturing CAR T therapies – BioPharma-Reporter.com
BioPharma-Reporter.com |
Juno: Centralised approach key to manufacturing CAR T therapies
BioPharma-Reporter.com Chimeric antigen receptor (CAR) T-cell therapies involve harvesting a patient's own T-cells, genetically modifying and multiplying them ex vivo, then infusing them back into the patient. The harvest and infusion takes place at a hospital or a clinic … |
